PubMed Health⌕ Search

Biomedical subjects

S Schur

Publications and source records attributed to S Schur.

4 recordsLinked to original sources
PubMed1991

An innovative program for multihandicapped deaf students using the FSSI.

Teachers in public schools now have more students with more severe disabilities than they did in the past. Unfortunately, efforts to provide them with a quality education have been hampered by a lack of focused instructional planning. This article describes an innovative program developed for deaf multihandicapped students that has created an integrated focus for instruction. The organizing framework for the program incorporates the Functional Skills Screening Inventory, a domain referenced assessment of living and working skills. This structured approach enables teachers to identify current functional levels, develop meaningful short- and long-term objectives, and monitor student progress throughout their educational programs. It also facilitates long-range planning and evaluation of the instructional program on an ongoing basis.

Adolescent↗
PubMed1981

Antibodies to inhalant fungal antigens in patients with asthma in Israel.

Thirty-eight of 97 asthmatic patients, seven of 26 normal subjects and two of 39 patients with chronic obstructive pulmonary disease (COPD) were found to have antibodies to one or more of the inhalant fungi and candida antigens assayed by both immunodiffusion and counterimmune electrophoresis. Atopy was demonstrated in 33 of the 38 asthmatic patients with antibodies. Eleven asthmatics had anti-alternaria antibodies while only two reacted to aspergillus.

Alternaria↗
PubMed1976

Metaproterenol in children with chronic asthma.

Metaproterenol sulfate was given to 25 children with asthma in the form of a syrup in a continuous treatment course of 180 days. Dosage amounted to 10 to 20 mg metaproterenol four times daily, depending on the patient's age and weight. Double-blind crossover tests of pulmonary function were run against placebo at the beginning and after 3 and 6 mo of treatment. The peak expiratory flow rate responses to metaproterenol consistently exceeded the responses to placebo, the differences proving statistically significant at several intervals after administration. Adverse reactions were limited to instances of hyperactivity in one child and of mild tremors in another; laboratory values remained normal throughout the 6-mo period except for low normal fasting blood sugar values recorded in 2 patients at the end of the study. Pulse rate increases occurring after metaproterenol were not considered clinically important.

Asthma↗